{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:17:55Z","timestamp":1793146675212,"version":"4.5.0"},"reference-count":178,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.exer.2023.109444","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T13:25:50Z","timestamp":1679405150000},"page":"109444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Identifying new drugs and targets to treat rapidly elevated intraocular pressure for angle closure and secondary glaucomas to curb visual impairment and prevent blindness"],"prefix":"10.1016","volume":"232","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4432-730X","authenticated-orcid":false,"given":"Najam A.","family":"Sharif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.exer.2023.109444_bib1","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1167\/iovs.13-12811","article-title":"Evaluation of retinal nerve fiber layer thickness and axonal transport 1 and 2 weeks after 8 hours of acute intraocular pressure elevation in rats","volume":"55","author":"Abbott","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2023.109444_bib2","article-title":"Normal and glaucomatous outflow regulation","volume":"11","author":"Acott","year":"2020","journal-title":"Prog. Retin. Eye Res."},{"issue":"3","key":"10.1016\/j.exer.2023.109444_bib3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/17460441.2017.1281244","article-title":"Rodent models of glaucoma and their applicability for drug discovery","volume":"12","author":"Agarwal","year":"2017","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.exer.2023.109444_bib4","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/bs.pbr.2015.04.012","article-title":"Retinal ganglion cell dendrite pathology and synapse loss: implications for glaucoma","volume":"220","author":"Agostinone","year":"2015","journal-title":"Prog. Brain Res."},{"issue":"5","key":"10.1016\/j.exer.2023.109444_bib5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1089\/jop.2009.0006","article-title":"Ocular hypotensive effects of anti-glaucoma agents in mice","volume":"25","author":"Akaishi","year":"2009","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"issue":"9","key":"10.1016\/j.exer.2023.109444_bib6","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1111\/bph.14971","article-title":"Adreno-melatonin receptor complexes control ion homeostasis and intraocular pressure \u2013 their disruption contributes to hypertensive glaucoma","volume":"177","author":"Alkozi","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"Suppl. 1","key":"10.1016\/j.exer.2023.109444_bib7","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/j.survophthal.2008.08.004","article-title":"Side-effects associated with prostaglandin analog therapy","volume":"53","author":"Alm","year":"2008","journal-title":"Surv. Ophthalmol."},{"issue":"3","key":"10.1016\/j.exer.2023.109444_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1167\/iovs.62.3.17","article-title":"NCX 667, a novel nitric oxide donor, lowers intraocular pressure in rabbits, dogs, and non-human primates and enhances TGF\u03b22-induced outflow in HTM\/HSC constructs","volume":"62","author":"Bastia","year":"2021","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.exer.2023.109444_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-98762-7","article-title":"Repeatability, reproducibility, and agreement of three tonometers for measuring intraocular pressure in rabbits","volume":"11","author":"Bertens","year":"2021","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.exer.2023.109444_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1167\/iovs.61.8.23","article-title":"Unaltered perception of suprathreshold contrast in early glaucoma despite sensitivity loss","volume":"61","author":"Bham","year":"2020","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2023.109444_bib11","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3389\/fncel.2019.00426","article-title":"Early-stage ocular hypertension alters retinal ganglion cell synaptic transmission in the visual thalamus","volume":"13","author":"Bhandari","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.exer.2023.109444_bib13","article-title":"Animal models of glaucoma","author":"Bouhenni","year":"2012","journal-title":"J. Biomed. Biotechnol."},{"issue":"7","key":"10.1016\/j.exer.2023.109444_bib189","doi-asserted-by":"crossref","first-page":"978","DOI":"10.2174\/1570159X15666170915142727","article-title":"Novel Therapeutics in Glaucoma Management","volume":"16","author":"Bucolo","year":"2018","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.exer.2023.109444_bib14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.coph.2012.09.012","article-title":"Pharmacological management of ocular hypertension: current approaches and future prospectives","volume":"13","author":"Bucolo","year":"2013","journal-title":"Curr. Opin. Pharmacol."},{"issue":"7","key":"10.1016\/j.exer.2023.109444_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070513","article-title":"Relationship between the magnitude of intraocular pressure during an episode of acute elevation and retinal damage four weeks later in rats","volume":"8","author":"Bui","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.exer.2023.109444_bib181","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1089\/jop.1986.2.9","article-title":"The ocular effects of xylazine in rabbits, cats, and monkeys","volume":"2","author":"Burke","year":"1986","journal-title":"J Ocul Pharmacol"},{"issue":"4","key":"10.1016\/j.exer.2023.109444_bib16","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2214-109X(20)30488-5","article-title":"The Lancet global health commission on global eye health: vision beyond 2020","volume":"9","author":"Burton","year":"2021","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.exer.2023.109444_bib17","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1167\/iovs.12-9483i","article-title":"The cell and molecular biology of glaucoma: axonopathy and the brain","volume":"53","author":"Calkins","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"1\u20132","key":"10.1016\/j.exer.2023.109444_bib18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1089\/jop.2016.0188","article-title":"The role of nitric oxide in the intraocular pressure lowering efficacy of latanoprostene bunod: review of nonclinical studies","volume":"34","author":"Cavet","year":"2018","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.exer.2023.109444_bib19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41433-018-0278-x","article-title":"Acute primary angle closure-treatment strategies, evidence and economic considerations","volume":"33","author":"Chan","year":"2019","journal-title":"Eye"},{"key":"10.1016\/j.exer.2023.109444_bib20","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.bmcl.2014.03.017","article-title":"In vivo optimization of 2,3-diaminopyrazine Rho kinase inhibitors","volume":"24","author":"Chen","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"13","key":"10.1016\/j.exer.2023.109444_bib21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1167\/iovs.62.13.12","article-title":"The intraocular pressure lowering effect of a dual kinase inhibitor (ITRI-E-(S)4046) in ocular hypertensive animal models","volume":"62","author":"Chen","year":"2021","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2023.109444_bib182","series-title":"J Ocul Pharmacol","first-page":"23","article-title":"Effects of D-timolol and L-timolol on ocular blood flow and intraocular pressure","volume":"6","author":"Chiou","year":"1990"},{"key":"10.1016\/j.exer.2023.109444_bib22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.brainres.2011.06.005","article-title":"Glial cell response and iNOS expression in the optic nerve head and retina of the rat following acute high IOP ischemia-reperfusion","volume":"403","author":"Cho","year":"2011","journal-title":"Brain Res."},{"issue":"3","key":"10.1016\/j.exer.2023.109444_bib165","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ophtha.2020.07.051","article-title":"Association of antihypertensive medication with retinal nerve fiber layer and ganglion cell-Inner plexiform layer thickness","volume":"128","author":"Chong","year":"2021","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.exer.2023.109444_bib155","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.coph.2012.09.008","article-title":"Oxidative stress and mitochondrial dysfunction in glaucoma","volume":"13","author":"Chrysostomou","year":"2013","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"10.1016\/j.exer.2023.109444_bib23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0161-6420(91)32345-5","article-title":"Displacement of the optic nerve head by acute changes in intraocular pressure in monkey eyes","volume":"8","author":"Coleman","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2023.109444_bib24","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0002-9394(98)00272-4","article-title":"The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma","volume":"126","year":"1998","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.exer.2023.109444_bib25","first-page":"71","article-title":"Emergencies in glaucoma: a review","volume":"296","author":"Collignon","year":"2005","journal-title":"Bull. Soc. Belge Ophtalmol."},{"issue":"3","key":"10.1016\/j.exer.2023.109444_bib26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.exer.2010.06.018","article-title":"Differential susceptibility to experimental glaucoma among 3 mouse strains using bead and viscoelastic injection","volume":"1","author":"Cone","year":"2010","journal-title":"Exp. Eye Res."},{"issue":"1","key":"10.1016\/j.exer.2023.109444_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.exer.2012.04.006","article-title":"The effects of anesthesia, mouse strain and age on intraocular pressure and an improved murine model of experimental glaucoma","volume":"9","author":"Cone","year":"2012","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.exer.2023.109444_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.100976","article-title":"Detecting retinal cell stress and apoptosis with DARC: progression from lab to clinic","volume":"86","author":"Cordeiro","year":"2022","journal-title":"Prog. Retin. Eye Res."},{"issue":"8","key":"10.1016\/j.exer.2023.109444_bib183","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/archopht.1987.01060080114039","article-title":"Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of Uveoscleral outflow by prostaglandin F2 alpha","volume":"105","author":"Crawford","year":"1987","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"10.1016\/j.exer.2023.109444_bib184","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1167\/tvst.9.8.33","article-title":"PnPP-19 peptide as a novel drug candidate for topical glaucoma therapy through nitric oxide release","volume":"9","author":"da Silva","year":"2020","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.exer.2023.109444_bib29","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1021\/acs.jmedchem.5b00828","article-title":"Discovery of molecular therapeutics for glaucoma: challenges, successes, and promising directions","volume":"59","author":"Donegan","year":"2016","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.exer.2023.109444_bib30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1006\/phrs.1997.0147","article-title":"Effects of beta-blockers in association with pilocarpine on rabbit intraocular pressure and heart rate","volume":"35","author":"Drago","year":"1997","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.exer.2023.109444_bib31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/biology8020031","article-title":"Mitochondrial dysfunction in the aging retina","volume":"8","author":"Eells","year":"2019","journal-title":"Biology"},{"issue":"6","key":"10.1016\/j.exer.2023.109444_bib32","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1523\/JNEUROSCI.1419-14.2015","article-title":"Characteristic patterns of dendritic remodeling in early-stage glaucoma: evidence from genetically identified retinal ganglion cell types","volume":"35","author":"El-Danaf","year":"2015","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.exer.2023.109444_bib33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10792-017-0795-9","article-title":"Pathophysiology of primary open-angle glaucoma from a neuroinflammatory and neurotoxicity perspective: a review of the literature","volume":"39","author":"Evangelho","year":"2019","journal-title":"Int. Ophthalmol."},{"issue":"3","key":"10.1016\/j.exer.2023.109444_bib34","first-page":"273","article-title":"Impaired axonal transport in glaucoma","volume":"41","author":"Fahy","year":"2016","journal-title":"Curr. Eye Res."},{"issue":"1","key":"10.1016\/j.exer.2023.109444_bib35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40123-020-00235-z","article-title":"Intraocular pressure measurement with pneumatonometry and a tonometer tip cover","volume":"9","author":"Ferguson","year":"2020","journal-title":"Ophthalmol Ther"},{"issue":"4","key":"10.1016\/j.exer.2023.109444_bib36","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S1350-9462(02)00008-3","article-title":"The impact of ocular blood flow in glaucoma","volume":"21","author":"Flammer","year":"2002","journal-title":"Prog. Retin. Eye Res."},{"issue":"6","key":"10.1016\/j.exer.2023.109444_bib37","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1167\/iovs.12-11427","article-title":"Antiglaucomatous effects of the activation of intrinsic angiotensin-converting enzyme 2","volume":"54","author":"Foureaux","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"7","key":"10.1016\/j.exer.2023.109444_bib38","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1089\/jop.2017.0146","article-title":"Effects of a novel selective EP2 receptor agonist, omidenepag isopropyl, on aqueous humor dynamics in laser-induced ocular hypertensive monkeys","volume":"34","author":"Fuwa","year":"2018","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"issue":"4","key":"10.1016\/j.exer.2023.109444_bib39","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1089\/jop.2020.0071","article-title":"Additive intraocular pressure-lowering effects of a novel selective EP2 receptor agonist, omidenepag isopropyl, combined with existing antiglaucoma agents in conscious ocular normotensive monkeys","volume":"37","author":"Fuwa","year":"2021","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"issue":"1","key":"10.1016\/j.exer.2023.109444_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/jop.2008.0089","article-title":"Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys","volume":"25","author":"Gabelt","year":"2009","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.exer.2023.109444_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fopht.2022.1007103","article-title":"Mechanism of retinal ganglion cell injury following acute increase in intraocular pressure","volume":"2","author":"Garner","year":"2022","journal-title":"Front Ophthalmol"},{"issue":"10","key":"10.1016\/j.exer.2023.109444_bib42","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.2460\/ajvr.1995.56.10.1325","article-title":"Evaluation of multiple doses of 4 and 6% timolol, and timolol combined with 2% pilocarpine in clinically normal beagles and beagles with glaucoma","volume":"56","author":"Gelatt","year":"1995","journal-title":"Am. J. Vet. Res."},{"issue":"6","key":"10.1016\/j.exer.2023.109444_bib43","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1167\/iovs.02-0600","article-title":"Functional characterization of retina and optic nerve after acute ocular ischemia in rats","volume":"44","author":"Grozdanic","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2023.109444_bib44","article-title":"Cell types and cell circuits in human and non-human primate retina","volume":"5","author":"Gr\u00fcnert","year":"2020","journal-title":"Prog. Retin. Eye Res."},{"issue":"2","key":"10.1016\/j.exer.2023.109444_bib45","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2174\/1567205018666210414113634","article-title":"Retinal changes in transgenic mouse models of Alzheimer's disease","volume":"18","author":"Guo","year":"2021","journal-title":"Curr. Alzheimer Res."},{"issue":"3","key":"10.1016\/j.exer.2023.109444_bib46","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10633-017-9586-x","article-title":"Pigmented and albino rats differ in their responses to moderate, acute and reversible intraocular pressure elevation","volume":"134","author":"Gurdita","year":"2017","journal-title":"Doc. Ophthalmol."},{"issue":"12","key":"10.1016\/j.exer.2023.109444_bib47","first-page":"1143","article-title":"The effect of topical pilocarpine on intraocular pressure and pupil size in the normotensive and glaucomatous beagle","volume":"16","author":"Gwin","year":"1977","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"2","key":"10.1016\/j.exer.2023.109444_bib48","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/bjophthalmol-2018-312724","article-title":"Recent advances in genetically modified animal models of glaucoma and their roles in drug repositioning","volume":"103","author":"Harada","year":"2019","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2023.109444_bib49","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/archopht.124.6.853","article-title":"Visual \ufb01eld defects and retinal ganglion cell losses in patients with glaucoma","volume":"124","author":"Harwerth","year":"2006","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.exer.2023.109444_bib50","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch. Ophthalmol."},{"issue":"Suppl. l #1","key":"10.1016\/j.exer.2023.109444_bib51","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0039-6257(02)00293-X","article-title":"Identification and characterization of the ocular hypotensive efficacy of Travoprost (Travatan\u00ae), a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist","volume":"47","author":"Hellberg","year":"2002","journal-title":"Surv. Ophthalmol."},{"issue":"9","key":"10.1016\/j.exer.2023.109444_bib164","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1167\/iovs.62.9.5","article-title":"Longitudinal In vivo changes in retinal ganglion cell dendritic morphology after acute and chronic optic nerve injury","volume":"62","author":"Henderson","year":"2021","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2023.109444_bib52","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1517\/14656566.2014.936850","article-title":"Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice","volume":"15","author":"Hollo","year":"2014","journal-title":"Expet Opin. Pharmacother."},{"issue":"2","key":"10.1016\/j.exer.2023.109444_bib54","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1167\/iovs.18-25252","article-title":"A highly selective rho-kinase inhibitor (ITRI-E-212) potentially treats glaucoma upon topical administration with low incidence of ocular hyperemia","volume":"60","author":"Hsu","year":"2019","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"5","key":"10.1016\/j.exer.2023.109444_bib55","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1167\/iovs.04-0993","article-title":"Acute effects of PGF2\u03b1 on MMP-2 secretion from human ciliary muscle cells: a PKC- and ERK-dependent process","volume":"46","author":"Husain","year":"2005","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"4","key":"10.1016\/j.exer.2023.109444_bib56","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1089\/jop.2008.0042","article-title":"Latanoprost-induced changes in rat intraocular pressure: direct or indirect?","volume":"24","author":"Husain","year":"2008","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.exer.2023.109444_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2021.108815","article-title":"Mitochondrial function is impaired in the primary visual cortex in an experimental glaucoma model","volume":"701","author":"Hvozda Arana","year":"2021","journal-title":"Arch. Biochem. Biophys."},{"issue":"12","key":"10.1016\/j.exer.2023.109444_bib58","doi-asserted-by":"crossref","first-page":"13728","DOI":"10.1021\/acsnano.9b07214","article-title":"Once daily pregabalin eye drops for management of glaucoma","volume":"13","author":"Ibrahim","year":"2019","journal-title":"ACS Nano"},{"issue":"8","key":"10.1016\/j.exer.2023.109444_bib185","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/bph.14328","article-title":"Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma","volume":"176","author":"Impagnatiello","year":"2019","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.exer.2023.109444_bib59","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11302-018-9614-7","article-title":"A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist","volume":"14","author":"Jacob","year":"2018","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.exer.2023.109444_bib60","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1073\/pnas.1706193114","article-title":"CRISPR-Cas9-based treatment of myocilin associated glaucoma","volume":"114","author":"Jain","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.exer.2023.109444_bib61","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1080\/02713683.2019.1629594","article-title":"Cyclic pattern of intraocular pressure (IOP) and transient IOP fluctuations in nonhuman primates measured with continuous wireless telemetry","volume":"44","author":"Jasien","year":"2019","journal-title":"Curr. Eye Res."},{"issue":"5","key":"10.1016\/j.exer.2023.109444_bib62","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11910-018-0831-9","article-title":"Intracranial and intraocular pressure at the lamina cribrosa: gradient effects","volume":"18","author":"J\u00f3hannesson","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"3","key":"10.1016\/j.exer.2023.109444_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2022.100216","article-title":"Neuroprotection, Neuroenhancement and Neurodegeneration of the retina and optic nerve","volume":"2","author":"Johnson","year":"2022","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.exer.2023.109444_bib64","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/S0140-6736(17)31469-1","article-title":"Glaucoma","volume":"390","author":"Jonas","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.exer.2023.109444_bib65","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1167\/iovs.13-13264","article-title":"IOP elevation reduces Schlemm's canal cross-sectional area","volume":"55","author":"Kagemann","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2023.109444_bib66","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2147\/OPTH.S131416","article-title":"Ocular hypotensive effects of a Rho-associated protein kinase inhibitor in rabbits","volume":"11","author":"Kamaruddin","year":"2017","journal-title":"Clin. Ophthalmol."},{"issue":"1","key":"10.1016\/j.exer.2023.109444_bib67","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-14938-0","article-title":"Increased synthesis and deposition of extracellular matrix proteins leads to endoplasmic reticulum stress in the trabecular meshwork","volume":"7","author":"Kasetti","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.exer.2023.109444_bib68","doi-asserted-by":"crossref","first-page":"446","DOI":"10.4103\/1673-5374.243712","article-title":"In vivo imaging of structural, metabolic and functional brain changes in glaucoma","volume":"14","author":"Kasi","year":"2019","journal-title":"Neural Regen Res"},{"issue":"6","key":"10.1016\/j.exer.2023.109444_bib69","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch. Ophthalmol."},{"issue":"12","key":"10.1016\/j.exer.2023.109444_bib70","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.1167\/iovs.17-22732","article-title":"Tunneling nanotubes are novel cellular structures that communicate signals between trabecular meshwork cells","volume":"58","author":"Keller","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2023.109444_bib72","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1167\/iovs.17-22745","article-title":"Pharmacologic characterization of omidenepag isopropyl, a novel selective EP2 receptor agonist, as an ocular hypotensive agent","volume":"59","author":"Kirihara","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2023.109444_bib73","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/bph.14327","article-title":"Discovery, characterization and clinical utility of prostaglandin agonists for treatment of glaucoma","volume":"176","author":"Klimko","year":"2019","journal-title":"Br. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.exer.2023.109444_bib74","doi-asserted-by":"crossref","first-page":"5732","DOI":"10.1167\/iovs.09-3814","article-title":"Functional changes in the retina during and after acute intraocular pressure elevation in mice","volume":"50","author":"Kong","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2023.109444_bib75","first-page":"2217","article-title":"Astrocyte and microglial activation in the lateral geniculate nucleus and visual cortex of glaucomatous and optic nerve transected primates","volume":"15","author":"Lam","year":"2009","journal-title":"Mol. Vis."},{"key":"10.1016\/j.exer.2023.109444_bib76","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ophtha.2012.08.047","article-title":"Reversal of lamina cribrosa displacement after intraocular pressure reduction in open-angle glaucoma","volume":"120","author":"Lee","year":"2013","journal-title":"Ophthalmol. Times"},{"issue":"3","key":"10.1016\/j.exer.2023.109444_bib77","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1089\/jop.2018.0095","article-title":"Dose-response of intracameral bimatoprost sustained-release implant and topical bimatoprost in lowering intraocular pressure","volume":"35","author":"Lee","year":"2019","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.exer.2023.109444_bib78","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.niox.2020.03.006","article-title":"Peroxynitrite is a novel risk factor and treatment target of glaucoma","volume":"99","author":"Lei","year":"2020","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.exer.2023.109444_bib79","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archopht.121.1.48","article-title":"Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial","volume":"121","author":"Leske","year":"2003","journal-title":"Arch. Ophthalmol."},{"issue":"10","key":"10.1016\/j.exer.2023.109444_bib80","doi-asserted-by":"crossref","first-page":"7205","DOI":"10.1167\/iovs.10-6868","article-title":"Tracking dendritic shrinkage of retinal ganglion cells after acute elevation of intraocular pressure","volume":"52","author":"Li","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"6","key":"10.1016\/j.exer.2023.109444_bib81","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1167\/iovs.13-13700","article-title":"Pilocarpine-induced dilation of Schlemm's canal and prevention of lumen collapse at elevated intraocular pressures in living mice visualized by OCT","volume":"55","author":"Li","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.exer.2023.109444_bib82","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1167\/iovs.17-23212","article-title":"Trabodenoson, an adenosine mimetic with A1 receptor selectivity lowers intraocular pressure by increasing conventional outflow facility in mice","volume":"59","author":"Li","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2023.109444_bib83","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ebiom.2019.05.059","article-title":"Impact of acute intraocular pressure elevation on the visual acuity of non-human primates","volume":"44","author":"Li","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.exer.2023.109444_bib85","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3390\/ph14090887","article-title":"In Silico screening and in vivo evaluation of potential CACNA2D1 antagonists as intraocular pressure-reducing agents in glaucoma therapy","volume":"14","author":"Li","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"1\u20132","key":"10.1016\/j.exer.2023.109444_bib86","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1089\/jop.2017.0023","article-title":"Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma","volume":"34","author":"Lin","year":"2018","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"issue":"2","key":"10.1016\/j.exer.2023.109444_bib87","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/ICU.0000000000000645","article-title":"Primary angle closure glaucoma genomic associations and disease mechanism","volume":"31","author":"Liu","year":"2020","journal-title":"Curr. Opin. Ophthalmol."},{"issue":"2","key":"10.1016\/j.exer.2023.109444_bib89","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1124\/jpet.115.231456","article-title":"Effect of melatonin and 5-methoxycarbonylamino-N-acetyltryptamine on the intraocular pressure of normal and glaucomatous mice","volume":"357","author":"Mart\u00ednez-\u00c1guila","year":"2016","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.exer.2023.109444_bib90","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1021\/jm030205t","article-title":"A novel and selective 5HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1\u2014(2-aminopropyl)-8,9-dihydropyrano-[3,2-e]indole","volume":"46","author":"May","year":"2003","journal-title":"J. Medicinal Chemsitry"},{"key":"10.1016\/j.exer.2023.109444_bib91","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1124\/jpet.103.049528","article-title":"Evaluation of the ocular hypotensive response of serotonin 5HT1A and 5HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys","volume":"306","author":"May","year":"2003","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"3","key":"10.1016\/j.exer.2023.109444_bib92","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/cxo.12333","article-title":"The interaction between intracranial pressure, intraocular pressure and lamina cribrosal compression in glaucoma","volume":"99","author":"McMonnies","year":"2016","journal-title":"Clin. Exp. Optom."},{"issue":"5","key":"10.1016\/j.exer.2023.109444_bib93","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1139\/Y10-026","article-title":"Oculohypotensive effect of perindopril in acute and chronic models of glaucoma in rabbits","volume":"8","author":"Mehta","year":"2010","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"5","key":"10.1016\/j.exer.2023.109444_bib172","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1007\/s12325-022-02069-6","article-title":"Efficacy and safety of omidenepag isopropyl 0.002% ophthalmic solution: a retrospective analysis of real-world data in Japan","volume":"39","author":"Miki","year":"2022","journal-title":"Adv. Ther."},{"issue":"15","key":"10.1016\/j.exer.2023.109444_bib94","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1167\/iovs.18-24838","article-title":"\u03949-Tetrahydrocannabinol and cannabidiol differentially regulate intraocular pressure","volume":"59","author":"Miller","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2023.109444_bib160","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-1-4939-7407-8_2","article-title":"Hypertonic Saline Injection Model of Experimental Glaucoma in Rats","volume":"1695","author":"Morrison","year":"2018","journal-title":"Meth Mol Biol"},{"issue":"4","key":"10.1016\/j.exer.2023.109444_bib95","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/IJG.0000000000001165","article-title":"Microvasculature of the optic nerve head and peripapillary region in patients with primary open-angle glaucoma","volume":"28","author":"Nascimento","year":"2019","journal-title":"J. Glaucoma"},{"key":"10.1016\/j.exer.2023.109444_bib96","article-title":"Effects of acute stress, general anesthetics, tonometry, and temperature on intraocular pressure in rats","volume":"10","author":"Nicou","year":"2021","journal-title":"Exp. Eye Res."},{"issue":"9","key":"10.1016\/j.exer.2023.109444_bib175","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1167\/iovs.05-1627","article-title":"The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey","volume":"47","author":"Nilsson","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.exer.2023.109444_bib97","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.tjo.2016.05.006","article-title":"Effect of potassium channel openers in acute and chronic models of glaucoma","volume":"6","author":"Panchal","year":"2016","journal-title":"Taiwan J Ophthalmol"},{"key":"10.1016\/j.exer.2023.109444_bib98","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1167\/iovs.13-12327","article-title":"Torsion of the optic nerve head is a prominent feature of normal-tension glaucoma","volume":"56","author":"Park","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2023.109444_bib99","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/ICU.0000000000000245","article-title":"Vascular and autonomic dysfunction in primary open-angle glaucoma","volume":"27","author":"Pasquale","year":"2016","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.exer.2023.109444_bib100","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/OPTH.S102181","article-title":"Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population","volume":"10","author":"Perera","year":"2016","journal-title":"Clin. Ophthalmol."},{"issue":"5","key":"10.1016\/j.exer.2023.109444_bib101","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/sj.bjp.0705118","article-title":"Ocular hypotensive effects of melatonin receptor agonists in the rabbit: further evidence for an MT3 receptor","volume":"138","author":"Pintor","year":"2003","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.exer.2023.109444_bib178","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.exer.2011.02.015","article-title":"Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma","volume":"93","author":"Prasanna","year":"2011","journal-title":"Exp Eye Res"},{"issue":"5","key":"10.1016\/j.exer.2023.109444_bib177","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1167\/iovs.18-23772","article-title":"A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers intraocular pressure in preclinical models, following topical ocular dosing","volume":"59","author":"Prasanna","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"5","key":"10.1016\/j.exer.2023.109444_bib179","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.exer.2009.05.002","article-title":"Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models","volume":"89","author":"Prasanna","year":"2009","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.exer.2023.109444_bib102","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.exer.2016.04.020","article-title":"ATP sensitive potassium channel openers: a new class of ocular hypotensive agents","volume":"158","author":"Roy Chowdhury","year":"2017","journal-title":"Exp. Eye Res."},{"issue":"5","key":"10.1016\/j.exer.2023.109444_bib103","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/jop.2020.0137","article-title":"Pharmacological profile and ocular hypotensive effects of cromakalim prodrug 1, a novel ATP-Sensitive potassium channel opener, in normotensive dogs and nonhuman primates","volume":"37","author":"Roy Chowdhury","year":"2021","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.exer.2023.109444_bib104","first-page":"2022","article-title":"Artificial intelligence-enabled retinal vasculometry for prediction of circulatory mortality, myocardial infarction and stroke","author":"Rudnicka","year":"2022","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2023.109444_bib180","doi-asserted-by":"crossref","first-page":"30583","DOI":"10.1038\/srep30583","article-title":"TRPV4 regulates calcium homeostasis, cytoskeletal remodeling, conventional outflow and intraocular pressure in the mammalian eye","volume":"6","author":"Ryskamp","year":"2016","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.exer.2023.109444_bib105","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1167\/iovs.08-2800","article-title":"Effects of prostanoid EP agonists on mouse intraocular pressure","volume":"50","author":"Saeki","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"8","key":"10.1016\/j.exer.2023.109444_bib106","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1248\/bpb.31.1590","article-title":"Ocular pharmacokinetic\/pharmacodynamic modeling for multiple anti-glaucoma drugs","volume":"31","author":"Sakanaka","year":"2008","journal-title":"Biol. Pharm. Bull."},{"issue":"# 4; Suppl. l","key":"10.1016\/j.exer.2023.109444_bib107","article-title":"Correlation of results from preclinical experimental models used for evaluation of FP prostaglandin agonists for therapy of glaucoma","volume":"39","author":"Sallee","year":"1998","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2023.109444_bib108","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1089\/jop.2015.0144","article-title":"Effect of hydrogen sulfide donors on intraocular pressure in rabbits","volume":"32","author":"Salvi","year":"2016","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"issue":"Suppl. 1","key":"10.1016\/j.exer.2023.109444_bib109","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1463-5224.2011.00958.x","article-title":"Effects of an unfixed combination of latanoprost and pilocarpine on the intraocular pressure and pupil size of normal dogs","volume":"15","author":"Sarchahi","year":"2012","journal-title":"Vet. Ophthalmol."},{"key":"10.1016\/j.exer.2023.109444_bib176","doi-asserted-by":"crossref","first-page":"107836","DOI":"10.1016\/j.exer.2019.107836","article-title":"Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey","volume":"189","author":"Savinainen","year":"2019","journal-title":"Exp Eye Res"},{"issue":"4","key":"10.1016\/j.exer.2023.109444_bib110","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/bjo.2004.052860","article-title":"Topically administered timolol and dorzolamide reduce intraocular pressure and protect retinal ganglion cells in a rat experimental glaucoma model","volume":"9","author":"Seki","year":"2005","journal-title":"Br. J. Ophthalmol."},{"issue":"10","key":"10.1016\/j.exer.2023.109444_bib111","first-page":"2002","article-title":"Retinal ganglion cell death after different transient periods of pressure-induced ischemia and survival intervals. A quantitative in vivo study","volume":"7","author":"Sell\u00e9s-Navarro","year":"1996","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.exer.2023.109444_bib112","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00061198-200106000-00013","article-title":"Effect of pilocarpine 4% in combination with latanoprost 0.005% or 8-iso prostaglandin E2 0.1% on intraocular pressure in laser-induced glaucomatous monkey eyes","volume":"10","author":"Serle","year":"2001","journal-title":"J. Glaucoma"},{"issue":"2","key":"10.1016\/j.exer.2023.109444_bib113","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00005344-200008000-00005","article-title":"Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma","volume":"36","author":"Shah","year":"2000","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"3","key":"10.1016\/j.exer.2023.109444_bib156","first-page":"22","article-title":"Ocular hypertension and glaucoma: a review and current perspectives","volume":"2","author":"Sharif","year":"2017","journal-title":"Int. J. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2023.109444_bib114","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1089\/jop.2017.0125","article-title":"iDrugs and iDevices discovery and development- preclinical assays, techniques and animal model studies for ocular hypotensives and neuroprotectants","volume":"34","author":"Sharif","year":"2018","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.exer.2023.109444_bib115","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1021\/acsptsci.0c00137","article-title":"Discovery to launch of anti-allergy (Emadine; Patanol\/Pataday\/Pazeo) and anti-glaucoma (Travatan; Simbrinza) ocular drugs, and generation of novel pharmacological tools such as AL-8810","volume":"3","author":"Sharif","year":"2020","journal-title":"ACS Pharmacology & Translational Science"},{"key":"10.1016\/j.exer.2023.109444_bib116","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.729249","article-title":"Therapeutic drugs and devices for tackling ocular hypertension and glaucoma, and need for neuroprotection and cytoprotective therapies","volume":"12","author":"Sharif","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.exer.2023.109444_bib169","doi-asserted-by":"crossref","first-page":"20","DOI":"10.5318\/wjo.v6.i3.20","article-title":"Human ciliary muscle cell responses to kinins: activation of ERK1\/2 and pro-matrix metalloproteinases secretion","volume":"6","author":"Sharif","year":"2016","journal-title":"World J. Ophthalmol."},{"key":"10.1016\/j.exer.2023.109444_bib170","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1089\/jop.2004.20.489","article-title":"Molecular pharmacology of the ocular hypotensive DP\/EP2 class prostaglandin AL-6598 and localization of DP and EP2 receptor sites in human eyes","volume":"20","author":"Sharif","year":"2004","journal-title":"J Ocular Pharmacol Ther"},{"key":"10.1016\/j.exer.2023.109444_bib117","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1089\/108076801753162726","article-title":"Levobetaxolol (Betaxon\u00ae) and other \u03b2\u2013adrenergic antagonists: preclinical pharmacology, IOP-lowering activity and sites of action in human eyes","volume":"17","author":"Sharif","year":"2001","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.exer.2023.109444_bib174","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1089\/108076803322660422","article-title":"Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells","volume":"19","author":"Sharif","year":"2003","journal-title":"J. Ocular Pharmacol. Therap."},{"key":"10.1016\/j.exer.2023.109444_bib118","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1167\/iovs.06-0062","article-title":"Human trabecular meshwork cells express functional serotonin-2 (5HT2) receptors: role in IOP reduction","volume":"47","author":"Sharif","year":"2006","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2023.109444_bib119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/jop.2006.0093","article-title":"AL-34662: a potent, selective, and efficacious ocular hypotensive serotonin-2 receptor agonist","volume":"23","author":"Sharif","year":"2007","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.exer.2023.109444_bib120","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.exer.2008.10.003","article-title":"Cabergoline: pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in cynomolgus monkey eyes","volume":"88","author":"Sharif","year":"2009","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.exer.2023.109444_bib171","doi-asserted-by":"crossref","first-page":"100037","DOI":"10.1016\/j.crneur.2022.100037","article-title":"Degeneration of retina-brain components and connections in glaucoma: Disease causation and treatment options for eyesight preservation","volume":"3","author":"Sharif","year":"2022","journal-title":"Current Research Neurobiology"},{"key":"10.1016\/j.exer.2023.109444_bib121","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/ddr.21174","article-title":"FR-190997, a non-peptide bradykinin B2-receptor partial agonist, is a potent and efficacious intraocular pressure lowering agent in ocular hypertensive cynomolgus monkeys","volume":"5","author":"Sharif","year":"2014","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.exer.2023.109444_bib122","article-title":"FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma","volume":"299","author":"Sharif","year":"2023","journal-title":"Exp. Eye Res."},{"issue":"Suppl 4","key":"10.1016\/j.exer.2023.109444_bib158","doi-asserted-by":"crossref","first-page":"S361","DOI":"10.1016\/S0039-6257(01)00219-3","article-title":"Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure","volume":"45","author":"Sherwood","year":"2001","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.exer.2023.109444_bib123","doi-asserted-by":"crossref","first-page":"495","DOI":"10.4103\/ijo.IJO_1130_17","article-title":"Simplifying \u201ctarget\u201d intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma","volume":"66","author":"Sihota","year":"2018","journal-title":"Indian J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.exer.2023.109444_bib124","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/vop.12679","article-title":"The effects of topical dorzolamide 2% and brinzolamide 1%, either alone or combined with timolol 0.5%, on intraocular pressure, pupil diameter, and heart rate in healthy cats","volume":"3","author":"Slenter","year":"2020","journal-title":"Vet. Ophthalmol."},{"issue":"1","key":"10.1016\/j.exer.2023.109444_bib125","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/alz.12179","article-title":"Retinal imaging in Alzheimer's and neurodegenerative diseases","volume":"17","author":"Snyder","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"15","key":"10.1016\/j.exer.2023.109444_bib126","first-page":"23","article-title":"Remodeling of the lamina cribrosa: mechanisms and potential therapeutic approaches for glaucoma","volume":"22","author":"Strickland","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.exer.2023.109444_bib127","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1476-5381.1990.tb14654.x","article-title":"L-662,583 is a topically effective ocular hypotensive carbonic anhydrase inhibitor in experimental animals","volume":"99","author":"Sugrue","year":"1990","journal-title":"Br. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.exer.2023.109444_bib128","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/glia.22507","article-title":"Reversible reactivity by optic nerve astrocytes","volume":"61","author":"Sun","year":"2013","journal-title":"Glia"},{"issue":"12","key":"10.1016\/j.exer.2023.109444_bib129","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1167\/iovs.61.12.15","article-title":"Intraocular pressure elevation compromises retinal ganglion cell light adaptation","volume":"61","author":"Tao","year":"2020","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2023.109444_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.108296","article-title":"Single transient intraocular pressure elevations cause prolonged retinal ganglion cell dysfunction and retinal capillary abnormalities in mice","volume":"201","author":"Tao","year":"2020","journal-title":"Exp. Eye Res."},{"issue":"5","key":"10.1016\/j.exer.2023.109444_bib131","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1167\/tvst.8.5.15","article-title":"\u03949-tetrahydrocannabinol derivative-loaded nanoformulation lowers intraocular pressure in normotensive rabbits","volume":"8","author":"Taskar","year":"2019","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.exer.2023.109444_bib163","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1167\/iovs.10-5289","article-title":"Oxidative stress and the regulation of complement activation in human glaucoma","volume":"51","author":"Tezel","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2023.109444_bib157","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmol"},{"key":"10.1016\/j.exer.2023.109444_bib132","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","article-title":"The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration","volume":"130","year":"2000","journal-title":"Am. J. Ophthalmol."},{"issue":"7","key":"10.1016\/j.exer.2023.109444_bib186","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1167\/iovs.05-1617","article-title":"Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys","volume":"48","author":"Tokushige","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.exer.2023.109444_bib133","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-50793-x","article-title":"Widespread brain reorganization perturbs visuomotor coordination in early glaucoma","volume":"9","author":"Trivedi","year":"2019","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.exer.2023.109444_bib134","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1167\/iovs.13-13003","article-title":"Effect of acute intraocular pressure challenge on rat retinal and cortical function","volume":"55","author":"Tsai","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"12","key":"10.1016\/j.exer.2023.109444_bib135","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/s41433-019-0484-1","article-title":"Relationship between intraocular pressure and retinal nerve fibre thickness loss in a monkey model of chronic ocular hypertension","volume":"33","author":"Tu","year":"2019","journal-title":"Eye (Lond)."},{"issue":"10","key":"10.1016\/j.exer.2023.109444_bib136","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/IJG.0000000000001325","article-title":"Role of pattern electroretinogram in ocular hypertension and early glaucoma","volume":"28","author":"Turkey","year":"2019","journal-title":"J. Glaucoma"},{"issue":"2","key":"10.1016\/j.exer.2023.109444_bib187","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1167\/iovs.13-13157","article-title":"AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia","volume":"55","author":"Van de Velde","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.exer.2023.109444_bib137","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1167\/iovs.16-19312","article-title":"Effects of chronic and acute intraocular pressure elevation on scotopic and photopic contrast sensitivity in mice","volume":"57","author":"Van der Heijden","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2023.109444_bib138","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2020.626056","article-title":"Neuronal and synaptic plasticity in the visual thalamus in mouse models of glaucoma","volume":"14","author":"Van Hook","year":"2021","journal-title":"Front. Cell. Neurosci."},{"issue":"Suppl. 1","key":"10.1016\/j.exer.2023.109444_bib139","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0039-6257(96)82028-5","article-title":"Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies","volume":"41","author":"Walters","year":"1996","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.exer.2023.109444_bib161","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1038\/s41598-018-24165-w","article-title":"The relationship between outflow resistance and trabecular meshwork stiffness in mice","volume":"8","author":"Wang","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.exer.2023.109444_bib140","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3109\/02713683.2010.512695","article-title":"Effect of SPP 301, an endothelin antagonist, on intraocular pressure in glaucomatous monkey eyes","volume":"36","author":"Wang","year":"2011","journal-title":"Curr. Eye Res."},{"issue":"1","key":"10.1016\/j.exer.2023.109444_bib141","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.exer.2011.11.019","article-title":"Effect of SPP 635, a renin inhibitor, on intraocular pressure in glaucomatous monkey eyes","volume":"94","author":"Wang","year":"2012","journal-title":"Exp. Eye Res."},{"issue":"4","key":"10.1016\/j.exer.2023.109444_bib142","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1177\/0271678X20935274","article-title":"Altered coupling of cerebral blood flow and functional connectivity strength in visual and higher order cognitive cortices in primary open angle glaucoma","volume":"41","author":"Wang","year":"2021","journal-title":"J. Cerebr. Blood Flow Metabol."},{"issue":"12","key":"10.1016\/j.exer.2023.109444_bib143","first-page":"2560","article-title":"EP3, but not EP2, FP, or TP prostanoid-receptor stimulation may reduce intraocular pressure","volume":"31","author":"Waterbury","year":"1990","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2023.109444_bib162","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: a review","volume":"311","author":"Weinreb","year":"2014","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.exer.2023.109444_bib145","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2460\/ajvr.1991.52.03.441","article-title":"Effects of topical administration of 2.0% pilocarpine on intraocular pressure and pupil size in cats","volume":"52","author":"Wilkie","year":"1991","journal-title":"Am. J. Vet. Res."},{"key":"10.1016\/j.exer.2023.109444_bib146","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s13346-014-0196-9","article-title":"Nanomedicine for glaucoma: sustained release latanoprost offers a new therapeutic option with substantial benefits over eyedrops","volume":"4","author":"Wong","year":"2014","journal-title":"Drug Deliv Transl Res"},{"issue":"5","key":"10.1016\/j.exer.2023.109444_bib173","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/jop.2018.0126","article-title":"A highly effective and ultra-long-acting anti-glaucoma drug, with a novel periorbital delivery method","volume":"35","author":"Woodward","year":"2019","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.exer.2023.109444_bib148","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1016\/j.ophtha.2014.06.035","article-title":"Optic nerve head deformation in glaucoma: the temporal relationship between optic nerve head surface depression and retinal nerve fiber layer thinning","volume":"121","author":"Xu","year":"2014","journal-title":"Ophthalmol. Times"},{"key":"10.1016\/j.exer.2023.109444_bib149","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1167\/iovs.14-16181","article-title":"IOP-lowering effect of ONO-9054, a novel dual agonist of prostanoid EP3 and FP receptors, in monkeys","volume":"56","author":"Yamane","year":"2015","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.exer.2023.109444_bib150","doi-asserted-by":"crossref","first-page":"104","DOI":"10.5005\/jp-journals-10078-1261","article-title":"Drug-induced acute angle-closure glaucoma: a review","volume":"13","author":"Yang","year":"2019","journal-title":"J. Curr. Glaucoma Pract."},{"issue":"6","key":"10.1016\/j.exer.2023.109444_bib151","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1463-5224.2011.00881.x","article-title":"Effect of acute intraocular pressure elevation on blood flow velocity and resistance in the rabbit ophthalmic artery","volume":"14","author":"Yang","year":"2011","journal-title":"Vet. Ophthalmol."},{"issue":"7","key":"10.1016\/j.exer.2023.109444_bib152","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1167\/iovs.12-9814","article-title":"Microbead-induced ocular hypertensive mouse model for screening and testing of aqueous production suppressants for glaucoma","volume":"53","author":"Yang","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2023.109444_bib153","article-title":"Progressive thinning of visual cortex in primary open-angle glaucoma of varying severity","volume":"10","author":"Yu","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.exer.2023.109444_bib188","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1089\/jop.1998.14.217","article-title":"Bunazosin reduces intraocular pressure in rabbits by increasing uveoscleral outflow","volume":"14","author":"Zhan","year":"1998","journal-title":"J Ocul Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.exer.2023.109444_bib154","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1167\/iovs.16-20807","article-title":"Establishment and characterization of an acute model of ocular hypertension by laser-induced occlusion of episcleral veins","volume":"58","author":"Zhang","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483523000659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483523000659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T05:23:33Z","timestamp":1758000213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483523000659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":178,"alternative-id":["S0014483523000659"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2023.109444","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying new drugs and targets to treat rapidly elevated intraocular pressure for angle closure and secondary glaucomas to curb visual impairment and prevent blindness","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2023.109444","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109444"}}